About Biomax Informatics

Biomax Informatics provides services and software solutions for efficient decision making and knowledge management at the intersection of life sciences, healthcare and information technologies. Biomax facilitates digital transformation within biotech, pharma, agriculture, food and chemical industries as well as research institutes.

Biomax offers a range of standard products addressing digitalization needs, like semantic search, brain imaging or clinical integration. These products are based on the BioXM™ technology platform of Biomax – the fully configurable and customizable Knowledge Management Environment. With more than 20 years of experience and around 50 employees – including numerous life scientists, data scientists and software developers with a scientific background – Biomax is a competent partner. Participation in multinational research projects keeps the Biomax team up-to-date with the latest research and technology and ensures that Biomax delivers state-of-the-art solutions to all customers at all times. Founded in 1997, Biomax Informatics is ISO 9001 and ISO 27001 certified and is headquartered in Planegg near Munich, Germany.
Professor Dr. Hans-Werner Mewes is one of the co-founders of Biomax and currently serves as Chairman of the Board of Directors. As an active researcher and professor, Mewes has championed scientific leadership in the business development and strategy of Biomax since its inception. After studying chemistry at Philipps University in Marburg, Mewes has held appointments at the University of Heidelberg, the European Molecular Biology Laboratory (EMBL) and the Max Planck Institute (MPI) for Biochemistry. In 1988, Dr. Mewes founded the Munich Information Center for Protein Sequences (MIPS) to collaborate with partners to build the international PIR Protein Sequence Database. He initiated the bioinformatics study program supported by the German Research Foundation in 1999. Since 2001, Dr. Mewes has been Professor of Bioinformatics at the Technische Universität München (TUM) and Director of the Institute of Bioinformatics and Systems Biology at the Helmholtz Zentrum München.
Dr. rer. nat. Klaus Heumann is one of the company’s co-founders and has been Chief Executive Officer of Biomax since its foundation. Heumann has lead the evolution of Biomax from a classic bioinformatics company to one of the leading knowledge management companies for the life sciences and healthcare. He brought together innovative and highly qualified life scientists, computer scientists and engineers to build a multidisciplinary team that truly understands the diverse challenges and underlying business and R&D processes in the wider life sciences arena. Dr. Heumann earned his PhD from the Technische Universität München (TUM) and was part of the Munich Information Center for Protein Sequences (MIPS) team that published the first sequenced eukaryotic genome, Saccharomyces cerevisiae. He led the project to compile the results on the yeast genome CD-ROM published by Science and Nature magazines. In 1996, Dr. Heumann received the Heinz Billing Prize of the Max Planck Society for his work on “Identification and visualization of duplications in the yeast genome.”
Professor Dr. Dmitrij Frishman is one of the co-founders of Biomax and is a member of the company’s Board of Directors. As an active researcher and recognized expert in computational biology, Dr. Frishman has been responsible for scientific project support and advancing scientific excellence at Biomax since its beginning. Dr. Frishman developed the Pedant-Pro™ Sequence Analysis Suite, the backbone of the company’s well-established portfolio of genome bioinformatics and systematic computational genome analysis tools. Dr. Frishman received his PhD in biochemistry from the Russian Academy of Sciences. Since then he has held appointments at the European Molecular Biology Laboratory (EMBL), the Max Planck Institute for Biochemistry and as Deputy Director of the Institute for Bioinformatics at the German National Center for Health and Environment. Dr. Frishman is currently Professor of Bioinformatics at the Technische Universität München (TUM).
Jonathan Sheridan acts as CEO of Biomax Informatics Inc., a wholly owned subsidiary of Biomax Informatics AG, and Vice President of Corporate Development and General Manager of Biomax Informatics AG for the Americas and Japan. Sheridan brings a deep understanding of business development and the commercialization of life science products to the Biomax Group. With over twenty years of sales, marketing and business development experience in the biotechnology industry, Sheridan has held several positions at leading biotech firms. As CCO at Integromics, a Spanish bioinformatics company, he managed global commercial operations and assisted the CEO and the founders with the transfer of global distribution responsibilities to PerkinElmer, Inc. Prior to Integromics, Sheridan was President and Chief Executive Officer with Integrated Genomics, Inc. and held senior positions with PerkinElmer Life and Analytical Sciences, Epicentre Biotechnologies, Genomica, Lion Biosciences, PerkinElmer Cetus, Beckman Coulter and Monsanto.
Dr. Gerhard Kranner is the founder and managing director of Viscovery Software GmbH (formerly Eudaptics), Biomax’s data mining subsidiary in Vienna, Austria. In 1994, Dr. Kranner founded the company, which was acquired by Biomax in 2007. As part of the Biomax Group, Dr. Kranner has established the company’s strong analytical capabilities and continues to drive the development of the scalable Viscovery data-mining suite, especially in the life science and healthcare arenas. Dr. Kranner has a background as theoretical physicist and received his PhD from the Vienna University of Technology.


Biomax Informatics GmbH (“company with limited liability”) was founded as spin-off of the Helmholtz Center hosting the Munich Information Center for Protein Sequences (MIPS).


Biomax becomes Biomax Informatics Aktiengesellschaft (AG, “company limited by privately held share ownership”).


The Biomax Group acquires data mining specialists Eudaptics (Austria). Eudaptics becomes Viscovery Software GmbH, renamed after its flagship product.


Biomax enters synthetic biology sector.


Biomax enters the health and clinical market and announces the CIRO+ Data Center enabling patient stratification and targeted medicine in COPD.


Biomax enters the mental health sector developing systems medicine solutions.


Biomax announces expansion of operations in the United States and the opening of its US headquarters near Madison, Wisconsin.


Biomax continues on the path of strong growth in pursuit of its vision to enable anyone to benefit from and contribute to collective know-how, experience and knowledge in the life sciences.

    Biomax has a well-earned reputation as a premier knowledge management software provider for commercial, academic and government organizations. We develop innovative software products and solutions based on a configurable, highly versatile knowledge management platform. Our business is based on customer orientation, tailor-made solutions, simplicity and functional value in a scientifically shaped environment. Our professional staff is dedicated to providing innovative products and services that help our client get the most out of their resources. For our location in Planegg near Munich, we are seeking qualified applicants for the following positions: Biomax offers you a varied and challenging position in an organization with a flat hierarchy and quick decision making within a pleasant, collegial and interdisciplinary environment. In addition, we support the ability to work independently (flex-time, home office). If you are interested in working in a truly interesting domain with international customers, please send your full application documents indicating the position of interest to: Biomax Informatics AG Robert-Koch-Str. 2 D-82152 Planegg Germany Phone: +49 89 895574-0 Fax: +49 89 895574-825 Email: